In an interview conducted at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy, Gail J. Roboz, MD, professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine, New York City, NY, discusses hot topics in acute myeloid leukemia presented at EHA 2025. Highlights include menin inhibitors for patients with NPM1 and KMT2A abnormalities, and the need for careful venetoclax dosing adjustments. Dr Roboz also reviewed how maintenance therapies, including oral azacitidine and transplants, in are important for both maintaining remission and improving quality of life.